Skip to Content

Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma 

New data show that epcoritamab is an effective off-the-shelf therapy for both CAR T-exposed and CAR T-naive patients with R/R LBCL who had already received prior lines of therapy.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top